Skip to main content
Journal cover image

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.

Publication ,  Journal Article
Hamilton, E; Kimmick, G; Hopkins, J; Marcom, PK; Rocha, G; Welch, R; Broadwater, G; Blackwell, K
Published in: Clin Breast Cancer
December 2013

BACKGROUND: Triple negative metastatic breast cancer can be difficult to treat with primarily cytotoxic options. Nab-paclitaxel has demonstrated improved PFS and tolerability compared with standard cremophor-solubilized paclitaxel; based on this, we examined the efficacy and safety of combining weekly nab-paclitaxel with carboplatin and bevacizumab in TNMBC. PATIENTS AND METHODS: In this phase II, multicenter trial, patients with first-line TNMBC received nab-paclitaxel (100 mg/m(2)) and carboplatin (area under the curve = 2) on days 1, 8, 15, and bevacizumab (10 mg/kg) on days 1 and 15 of a 28-day cycle. The primary end point was safety and tolerability and secondary end points included PFS, ORR, and CBR. PFS was calculated using the Kaplan-Meier method. RESULTS: Between July 16, 2007, and October 3, 2011, 34 patients were enrolled at 4 centers. Median age was 50.0 (range, 30-76) years and 77% (n = 26) of patients received previous adjuvant therapy. Median PFS was 9.2 months (95% confidence interval [CI], 7.8-25.1 months). The CBR was 94% (95% CI, 80%-99%), and ORR was 85% (95% CI, 69%-95%) for the combination. The regimen was well tolerated with the most common grade 3/4 adverse events being neutropenia (n = 18; 53%) and thrombocytopenia (n = 6; 18%), with other serous events including 1 grade 3 and 1 grade 4 thrombotic event and 1 febrile neutropenia. CONCLUSION: The combination of nab-paclitaxel, bevacizumab, and carboplatin as first-line treatment for TNMBC was efficacious and well tolerated. The PFS, CBR, and ORR, and tolerability of the regimen, compares favorably with other standard first-line therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Breast Cancer

DOI

EISSN

1938-0666

Publication Date

December 2013

Volume

13

Issue

6

Start / End Page

416 / 420

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Prognosis
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hamilton, E., Kimmick, G., Hopkins, J., Marcom, P. K., Rocha, G., Welch, R., … Blackwell, K. (2013). Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer, 13(6), 416–420. https://doi.org/10.1016/j.clbc.2013.08.003
Hamilton, Erika, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, and Kimberly Blackwell. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.Clin Breast Cancer 13, no. 6 (December 2013): 416–20. https://doi.org/10.1016/j.clbc.2013.08.003.
Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013 Dec;13(6):416–20.
Hamilton, Erika, et al. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.Clin Breast Cancer, vol. 13, no. 6, Dec. 2013, pp. 416–20. Pubmed, doi:10.1016/j.clbc.2013.08.003.
Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, Broadwater G, Blackwell K. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013 Dec;13(6):416–420.
Journal cover image

Published In

Clin Breast Cancer

DOI

EISSN

1938-0666

Publication Date

December 2013

Volume

13

Issue

6

Start / End Page

416 / 420

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Prognosis
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female